AB Science’s latest update narrows the story around two priorities: masitinib in ALS and AB8939 in AML. The key change is not FY25 revenue, but clearer capital allocation, a more defined ALS Phase 3 setup, and a firm CTFI offer that adds potential risk-sharing around AB23005. MS and AD remain meaningful upside, but are now more partnership-led given scale and commercial requirements. Near-term focus should be ALS funding, European organizational readiness, first-patient timing, and continue AML data generation.